Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Cancer drug developer Merrimack Pharmaceuticals Inc. has netted $95.6mm through its initial public offering by selling 14.3mm common shares at $7. The company originally filed in August 2011 and announced in January 2012 that it hoped to sell 16.67mm shares between $8-10 apiece. Shortly thereafter, there was speculation that Merrimack would postpone or withdraw its filing due to market conditions, but an accelerated S1 approval led the company to a successful pricing.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?